Donepezil for Alzheimer's disease in clinical practice - The DONALD study: A multicenter 24-week clinical trial in Germany

Dementia and Geriatric Cognitive Disorders

Volumn 18, Issue 1, 2004, Pages 37-43

  Froelich, L ^a   Gertz, H J ^b   Heun, R ^c   Heuser, I ^d   Jendroska, K ^d   Kornhuber, J ^e   Kurz, A ^f   Mueller Thomsen, T ^g   Ries, F ^h   Waechtler, C ⁱ   Metz, M ^j   Goebel, C ^k  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF HAMBURG   (Germany)

^h Pract for Neurology and Psychiatry   (Germany)

ⁱ Klinikum Nord   (Germany)

^j Eisai GmbH   (Germany)

^k PFIZER INC   (United States)

more..

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Dementia w; Donepezil; Electrocardiography; Fischer somatic or undesired effects check list; Nurses observation scale for geriatric patients

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL;

ABDOMINAL PAIN; ADULT; AGED; AKATHISIA; ALZHEIMER DISEASE; ANOREXIA; APPETITE DISORDER; ARTICLE; AUTONOMIC DYSFUNCTION; BRADYCARDIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONFUSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; EXTRASYSTOLE; FATIGUE; FECES INCONTINENCE; FEMALE; GASTROINTESTINAL SYMPTOM; GERMANY; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERKINESIA; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PAIN; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; RESTLESSNESS; SYNCOPE; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; URINE INCONTINENCE; VISUAL DISORDER; VOMITING; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASES; CHOLINESTERASE INHIBITORS; ELECTROCARDIOGRAPHY; FEMALE; GERMANY; HEMODYNAMIC PROCESSES; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PIPERIDINES; TREATMENT OUTCOME;

EID: 3042550038     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077733     Document Type: Article

References (23)

1. Davies P, Maloney AJ: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;ii:1403.
2. Davis RE, Doyle PD, Carroll RT, Emmerling MR, Jaen J: Cholinergic therapies for Alzheimer's disease. Arzneimittelforsch 1995;45:425-431.
3. Rogers SL, Friedhoff LT and the Donepezil Study Group: The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicenter, randomized, doubleblind trial. Dementia 1996;7:293-303.
4. Rogers SL, Doody RS, Mohs RC, Friedhoff LT: Donepezil improves cognition and global function in Alzheimer's disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158:1021-1031.
5. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Donepezil Study Group: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
6. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT: The effects of donepezil in Alzheimer's disease. Results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-244.
7. Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, Walsh KL, Corwin C, Daffner KR, Friedman P, Meadows ME, Sperling RA, Growdon JH: Donepezil therapy in clinical practice. Arch Neurol 2000;57:94-99.
8. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
9. Spiegel R, Brunner C, Ermini-Fünfschilling D, Monsch A: A new behavioral assessment scale for geriatric out- and in-patients: The NOSGER (Nurses' Observation Scale for Geriatric Patients). J Am Geriatr Soc 1991;39:339-347.
10. Angus JWS, et al: Internationale Skalen für Psychiatrie, ed 4 revised. Göttingen, Collegium Internationale Psychiatriae Scalarum, Beltz Test GmbH, 1996, pp 71-73.
11. Fischer-Cornelssen KA: Multifokale Psychopharmakaprüfung (Multihospital Trial). Drug Res 1974;24:1706-1724.
12. Lavori, PW, Dawson R, Shera D: A multiple imputation strategy for clinical trials with truncation of patient data. Stat Med 1995;14:1913-1925.
13. Little RJA , Rubin DB: Statistical Analysis and Missing Data. New York, Wiley, 1987.
14. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, the Donepezil MSAD Study Investigators Group: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620.
15. Brooks JO 3rd, Yesavage JA, Taylor J, Friedman L, Tanke ED, Luby V, Tinklenberg J: Cognitive decline in Alzheimer's disease: Elaborating on the nature of the longitudinal factor structure of the Mini-Mental State Examination. Int Psychogeriatr 1993;5:135-146.
16. Clark CM, Sheppard L, Fillenbaum GG, Galasko D, Morris JC, Koss E, Mohs R, Heyman A: Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: A clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 1999;56:857-862.
17. McRae T, Orazem J: A large, communitybased open-label trial of donepezil in the treatment of Alzheimer's diesase (AD) (abstract). J Am Geriatr Soc 1999;47:S63.
18. Alom J, Leblhuber F, Cras P, et al: Donepezil for the treatment of Alzheimer's disease: A multinational clinical experience study (abstract). Int Psychogeriatr 2001;13(suppl 2):245S.
19. Bilikiewicz A, Opala G, Podemski R, Puzynski S, Lapin J, Soltys K, Ochudlo S, Barcikowska M, Pfeffer A, Bilinska M, Paradowski B, Parnowski T, Gabryelewicz T: An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting. Med Sci Monit 2002;8:PI9-15.
20. Schmidt R, Lechner A, Petrovic K: Rivastigmine in outpatient services: experience of 114 neurologists in Austria. Int Clin Psychopharmacol 2002;17:81-85.
21. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD, for the '312' Study Group: A 1-year, placebo controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-488.
22. Dunn NR, Pearce GL, Shakir SA: Adverse effects associated with the use of donepezil in general practice in England. J Psychopharmacol 2000;14:406-408.
23. Walsh E, Dourish J: Prolonged QT interval with rivastigmine. Br J Psychiatry 2002;180:466.